Consistent with the role of the phosphatases in limiting T cell anti-cancer responses, as described using gene knockout models, PTPN1 and PTPN2 inhibitors have been used to enhance anti-tumour immunity and sensitise tumours to other immunotherapy modalities in pre-clinical models [27,29,30]. This evidence concerns the gene PTPN2 and neoplasm.